Company / Operating Cash Flow
bioAffinity Technologies, Inc. Operating Cash Flow History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$7.3M
FY2025
5-year range
-$7.3M / -$2.0M
FY2022-FY2025
Trend
-20.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 3 consecutive years, from -$2M in FY2022 to -$7M in FY2025.
Based on SEC 10-K filings.
-$7M in FY2025.
Declined from -$4M to -$7M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- bioAffinity Technologies, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 20.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$7.3M | -20.3% |
| FY2024 | -$6.0M | -48.3% |
| FY2023 | -$4.1M | -98.7% |
| FY2022 | -$2.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026